Mapping metabolite change in the mouse brain after esketamine injection by ambient mass spectrometry imaging and metabolomics.
Guan-Xi Liu, Ze-Lin Li, Su-Yan Lin, Qian Wang, Zheng-Yi Luo, Kai Wu, Yan-Lin Zhou, Yu-Ping Ning
Frontiers in Psychiatry May 10, 2023 DOI: 10.3389/fpsyt.2023.1109344 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Preclinical spatial metabolomics study Peer reviewed |
|---|---|
| Population | Brain tissue (whole-brain metabolic mapping in an animal model after esketamine injection) |
| Intervention | Esketamine |
| Topics | Depression Ketamine Esketamine |
| Keywords | Antidepressant Mass spectrometry imaging Spatial metabolomics |
| Key points | Using AFADESI-mass spectrometry imaging, the authors report that esketamine injection produced metabolite changes across the brain, with glycerophospholipid metabolism altered mainly around the brain and sphingolipid metabolism altered mainly in the globus pallidus, the region showing the most significant metabolite change. They propose this spatial metabolic mapping helps explore esketamine's potential antidepressant mechanism. |
Abstract
Ketamine is a new, fast, and effective antidepression treatment method; however, the possible dissociation effects, sensory changes, abuse risk, and the inability to accurately identify whether patients have a significant response to ketamine limit its clinical use. Further exploration of the antidepressant mechanisms of ketamine will contribute to its safe and practical application. Metabolites, the products of upstream gene expression and protein regulatory networks, play an essential role in various physiological and pathophysiological processes. In traditional metabonomics it is difficult to achieve the spatial localization of metabolites, which limits the further analysis of brain metabonomics by researchers. Here, we used a metabolic network mapping method called ambient air flow-assisted desorption electrospray ionization (AFADESI)-mass spectrometry imaging (MSI). We found the main changes in glycerophospholipid metabolism around the brain and sphingolipid metabolism changed mainly in the globus pallidus, which showed the most significant metabolite change after esketamine injection. The spatial distribution of metabolic changes was evaluated in the whole brain, and the potential mechanism of esketamine's antidepressant effect was explored in this research.
Comparable studies
Other preclinical and animal studies on esketamine for depression, most cited first.
Citations in the library
Cited by 2
- Evidence from preclinical and clinical metabolomics studies on the antidepressant effects of ketamine and esketamine. Neuroscience Letters May 14, 2024
- Esketamine alleviates depressive-like behavior in neuropathic pain mice through the METTL3-GluA1 pathway. Cell Biology and Toxicology January 29, 2025
Cites 7
- A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression Archives of General Psychiatry August 1, 2006
- Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial American Journal of Psychiatry August 28, 2013
- Ketamine: 50 Years of Modulating the Mind Frontiers in Human Neuroscience November 29, 2016
- Glutamatergic receptor and neuroplasticity in depression: Implications for ketamine and rapastinel as the rapid-acting antidepressants. Biochemical and Biophysical Research Communications 2022
- Comparative metabolomic analysis in plasma and cerebrospinal fluid of humans and in plasma and brain of mice following antidepressant-dose ketamine administration Translational Psychiatry May 2, 2022
and 2 more in the library